Analyst RatingAnalyst reiterates Neutral rating and $2 price target.
EarningsNet loss was $7.6M, or ($0.25) per share, lower than our estimated loss of $10.6M.
RisksRisks include lower-than-projected uptake of products, inability to maintain regulatory compliance, inability to develop additional products targeting infectious diseases, and potential dilution risk.